Clinical Trials in Washington

Showing 4021-4040 of 9,462 trials

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

NCT03094832

This is an open label, Phase 1/2 study of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) (MOSAIC).

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)50 participantsStarted May 2017

Atlanta, Georgia, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +8 more locations

COMPLETEDPhase 242 miles

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

NCT03515044

Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).

Overt Hepatic Encephalopathy

Bausch Health Americas, Inc.71 participantsStarted Sep 2018

Corona del Mar, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +31 more locations

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

Find Trials by Condition in Washington

Acquired Methemoglobinemia Observational Registry

Assessing Health Electronically for Adolescent and Young Adult Oncology

N99-02: Melphalan and Buthionine Sulfoximine

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

Coached, Coordinated, Enhanced Neonatal Transition (CCENT)

ShockPulse-SE vs. Trilogy Trial: Comparing the Performance of Two Intracorporeal Lithotripters for Removal of Large Renal Calculi

iPeer2Peer Program for Adolescents With Inflammatory Bowel Disease

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Comparison of Devices for Atrial Septal Defects Closure: A Pilot Study

Ganaxolone Treatment in Children With Fragile X Syndrome

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)